Le Lézard
Classified in: Health, Science and technology
Subject: CCA

Theravance Biopharma to Report First Quarter 2024 Financial Results on May 13, 2024


DUBLIN, April 29, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its first quarter 2024 financial results and provide a business update after market close on Monday, May 13, 2024. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm ET (2:00 pm PT/10:00 pm IST) that day.

Conference Call Information

To participate in the live call by telephone, please pre-register here. Those interested in listening to the conference call live via the internet may do so by visiting Theravance Biopharma's website at www.theravance.com, under the Investors section, Events and Presentations.

A replay of the webcast will be available on Theravance Biopharma's website for 30 days through June 12, 2024.

About Theravance Biopharma

Theravance Biopharma, Inc.'s focus is to deliver Medicines that Make a Difference® in people's lives. In pursuit of its purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Ampreloxetine, its late-stage investigational once-daily norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA), has the potential to be a first in class therapy effective in treating a constellation of cardinal symptoms in MSA patients. The Company is committed to creating/driving shareholder value.

For more information, please visit www.theravance.com.

THERAVANCE BIOPHARMA®, THERAVANCE® and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries).

YUPELRI® is a registered trademark of Mylan Specialty L.P., a Viatris company. Trademarks, trade names or service marks of other companies appearing in this press release are the property of their respective owners.

Contact:
[email protected]
650-808-4045

 

SOURCE Theravance Biopharma, Inc.


These press releases may also interest you

at 04:31
Prosthetic Heart Valve Market to Reach $30.3 billion, Globally, by 2035 at 11.1% CAGR: Allied Market Research
Allied Market Research published a report, titled, "Prosthetic Heart Valve Market by Product (Mechanical Heart Valve, Tissue Heart Valve, and Transcatheter Heart Valve): Global Opportunity...

at 04:30
LoRaWAN® Temperature and Humidity Sensors for Food Safety, Pharmaceutical and Beyond
In industries like pharmaceuticals, food, and logistics, maintaining the integrity of products throughout the supply chain is critical. Temperature and humidity are two key parameters that can significantly affect the quality and safety of goods,...

at 04:25
Enhanc3D Genomics Appoints Hazel Jones as Chief Executive Officer
Enhanc3D Genomics, a company developing disruptive technologies to unlock the 3D genome for use in novel target identification and unique patient stratification, today announced the appointment of Hazel Jones as Chief Executive Officer, after a...

at 04:00
Uniken Introduces Certainty in Your Handtm Through Palm Vein Authentication
Uniken, a leading provider of security, authentication, and identity verification, announces at the Temenos Community Forum 2024 the release of Palm Vein Authentication for in-branch, rural and inclusive banking on its REL-ID platform. Financial...

at 03:55
VTT Info: A new revolutionary method accelerates the development of sustainable biomaterials from years to minutes
A groundbreaking study, published in the scientific journal Advanced Materials, on 6 May 2024, led by researchers of VTT Technical Research Centre of Finland, introduces a transformative approach that integrates synthetic biology with advanced...

at 03:05
MRM Health to Present Positive Clinical Data from MH002 in Ulcerative Colitis at Digestive Disease Week (DDW)
MRM Health NV, a clinical-stage biopharmaceutical company developing innovative therapeutics for inflammatory, CNS and metabolic diseases, today announced it will present positive data for its lead asset, MH002, a live microbial consortium therapy...

More news about Health...


News published on and distributed by: